Amarin expects positive cash flow for the full year 2026, driven by a completed restructuring and growing international demand. CEO Aaron Berg said the company's restructuring is now complete, resulting in a significantly lower cost base, and that VASCEPA's share of the U.S. icosapent ethyl market rose to 48% as of June 30, 2026, up from 43% a year earlier. In Europe, in-market demand for VAZKEPA under the Recordati partnership rose 69% in the second quarter of 2026 compared to the same period last year. CFO Peter Fishman reported second-quarter total net revenue of $42.2 million, with U.S. product revenue of $32.2 million and Europe product revenue of $5.4 million, while operating expenses fell 59% to $27 million. The company ended the quarter with $314.6 million in cash and investments and no debt, generating $7 million of positive cash flow from operations.
RecordatiRecordati's partnership with Amarin shows 69% demand growth for VAZKEPA in Europe, boosting Recordati's revenue.
Amarin Corporation PLC